SH3KBP1 Promotes Glioblastoma Tumorigenesis by Activating EGFR Signaling

Hai Song, Yanpei Wang, Chaojia Shi, Jianxiang Lu, Tian Yuan and Xiangpeng Wang*

Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming, China

Glioblastoma (GBM) is the most common and aggressive brain tumor in adults. Overexpression or activation of epidermal growth factor receptor (EGFR) occurs commonly in multiple human cancers and promotes tumorigenesis. However, the underlying molecular mechanism of EGFR aberrant activation and the downstream signaling pathways remains largely unknown. In this study, we report that both SH3-domain kinase binding protein 1 (SH3KBP1) mRNA and protein levels are highly expressed in GBM and its high expression is associated with worse survival of glioma patients. In addition, we provide evidence that SH3KBP1 is prominently expressed in GBM stem cells (GSCs) and have potential to serve as a novel GSCs marker. Moreover, silencing SH3KBP1 dramatically impairs GBM cell proliferation, migration and GSCs self-renewal ability in vitro and xenograft tumors growth in vivo. Most importantly, we found that SH3KBP1 directly interacts with EGFR and may act as an adaptor protein to transduce EGFR signaling. Together, our work uncovers SH3KBP1 as a novel regulator of oncogenic EGFR signaling and also as a potential therapeutic target for GBM patients with EGFR activation.

Keywords: glioblastoma, SH3KBP1, epidermal growth factor receptor, adaptor, glioblastoma stem cells

INTRODUCTION

Glioblastoma (GBM, WHO IV glioma) is the most common and lethal tumor of the central nervous system, which accounts for 15.4% of all primary brain tumors and 45.6% of primary malignant brain tumors (1–3). Despite recent advances in GBM clinical treatment, the overall survival of GBM patients remains only 15 months (4, 5). Glioma stem cells (GSCs), which are a small subpopulation of cells reside at GBM niches and are characterized by having self-renewal ability and tumor-initiating capacity simultaneously, which have shown to account for GBM initiation, therapeutic resistance and tumor relapse (6–8). Thus, new therapies that specifically delete GSCs may be developed by promising initiatives, which are urgently needed for glioma patients’ clinical therapy.

A hallmark of human cancers is aberrantly active oncogenic signaling activated by amplified and overexpressed oncopogenes (9). Epidermal growth factor receptor (EGFR) is a trans-membrane receptor tyrosine kinase of the ERBB family that is an essential enzyme for cell proliferation and tumorigenesis (10). Upon binding to ligands, including EGF or TGF-α, EGFR forms heterodimers or homodimers, leading to its C-terminal tail autophosphorylation and activates downstream signaling through its docking site of SRC homology domain (11). EGFR signaling pathways have...
well been established to play essential roles in regulating fundamental development stage and pathological processes. An overexpression of either EGFR or EGFR-activating mutations has been documented in various human tumors and is correlated with a poor clinical prognosis (12–14). It is well established that activation of EGFR signaling plays critical roles in promoting multiple tumor cell proliferation, migration, therapeutic resistance and cancer stem cell self-renewal maintenance (15, 16). Thus, it is important to identify more therapies targeting EGFR as new clinically applicable drugs.

SRC homology 3 (SH3) domain is composed of 50 amino acid residues, which is an evolutionarily conserved sequence in the non-catalytic part of receptor tyrosine kinases (17). SH3KBP1 was functionally identified as an adaptor protein and plays key roles in activating B cells and preventing EGFR degradation via its two PXXXPR motifs in carboxyl terminus, which specifically binds to SH3 domain kinases (18, 19). In cancer initiation and development, SH3KBP1 has been reported to inhibit Prolyl Hydroxylase 2 (PHD2) binding with Hypoxia-Inducible Factor (HIF) and promotes cancer progression (20). In addition, SH3KBP1 has been documented to interact with c-Cbl and promote breast cancer cell invasion (21). However, the biological function of SH3KBP1 and its underlying molecular mechanism in regulating glioma tumorigenesis remains largely unknown. Based on this background, we focused on investigating the functional roles of SH3KBP1 in glioma tumorigenesis.

**MATERIALS AND METHODS**

**Tissues Collection**

Total of 27 pairs of glioma samples were collected from First Affiliated Hospital of Kunming Medical University and the study was carried out under the approval of Ethics Committee of First Affiliated Hospital of Kunming Medical University. Patients who received either radiotherapy or chemotherapy before surgery were excluded. Prior to this study, all patients signed the written informed consent.

**Cell Lines and Transfection**

Human GBM cell lines (U87, U251, and LN229) used in this study were all purchased from ATCC (Manassas, USA) and then cultured in DMEM (Life Technologies). The DMEM culture medium was supplemented with 10% FBS and 1% antibiotics. Cells were all cultured under a chamber with 95% O2, 5% CO2 and 37°C.

For lentiviral short hairpin RNA (shRNA) transfection, control shRNA (Ctrl shRNA) or target SH3KBP1 shRNA were cloned into pLKO.1 and co-transfected into 293T with pMD2.G and pSPAX2, respectively. After 48 h, the virus particles were harvested and passed through a 0.22-mm filter. The parental cells were infected with the virus supernatant for another 48 h and selected using 1 µg/ml puromycin for 7 days. After selection, the stable cell lines were used for further study. Sequence of shRNA was as follow. SH3KBP1 shRNA: CCGCAGACGTGTC TGAGATTG. Control shRNA: GCAGCCTAACGCACATGAT.

**Immunofluorescence Staining**

Briefly, 4% paraformaldehyde was used to fix human surgical glioma specimens for 15 min. Samples were blocked with 10% normal donkey serum with 0.2% Triton X-100 in PBS for 60 min at room temperature and then incubated with primary antibodies overnight at 4°C, followed by incubation with appropriate secondary fluorescently labeled antibodies (Invitrogen) for 2 h at room temperature. Nuclei were counterstained with Hoechst. Two GBM specimens were used in this study.

**Immunohistochemistry (IHC)**

Human tumor or mouse xenograft tumor tissues were fixed in 4% paraformaldehyde, dehydrated and embedded in paraffin. Then, paraffin-embedded tissues were cut into 4-µm thick sections. After being de-paraffinized and rehydrated through a descending alcohol series, the sections were followed by antigen retrieval. After blocking with 1% BSA for 30 min at room temperature, the sections were incubated with antibodies against Ki67 and p-STAT3 overnight at 4°C and incubate with secondary antibody conjugates with HRP for 30 min at 37°C and examined by using diaminobenzidine detection. Thereafter, sections were stained with hematoxylin for nuclear staining and finally observed and photographed under a microscope. SH3KBP1 (1:100) (Cell signaling technology, 12304), Ki67 (1:500) (Cell signaling technology, 9449).

**In Vitro Limiting Dilution and Spheres Formation Assay**

For spheres formation assay, 50,000 U87 and U251 cells expressing with or without SH3KBP1 shRNA were seeded in ultra-low attachment six-well plates (Corning, USA) and cultured in Dulbecco’s modified Eagle’s medium/F12 (Life Technologies) supplemented with B27 (Invitrogen, USA), N2 (Invitrogen, USA), 20 ng/ml epidermal growth factor (Millipore) and 20 ng/ml basic fibroblast growth factor (Millipore). After two weeks, spheres larger than 50 µm were counted and representative images were pictured under stereomicroscope (Olympus, Tokyo, Japan). For in vitro limiting dilution assay, single dissociated U87 and U251 cells were plated in ultra-low attachment 96-well plates (Corning, USA) at density of 5, 10, 20, 50, 100, or 200 cells per well with above mentioned sphere formation medium. After culturing without serum for 14 days, formatted spheres were counted in each well and sphere formation frequency was calculated using online in vitro limiting dilution analysis (http://bioinf.wehi.edu.au/software/elda/).

**Colony Formation Assay**

The single U251 and U87 cells expressing with or without SH3KBP1 shRNA were plated to six-well plates at a density of 3,000 cells per well. Cells were cultured for 14 days to form colony and were fixated with 4% formaldehyde and then stained with 0.5% crystal violet. Colonies visible to the naked eye were imaged and counted manually.
Wound Healing Assay
Cells were seeded to six-well plates at a density of 600,000 cells per well and the scratch was created by a 200 µl pipette tip when cell grown to 80% confluence. The wound closure was imaged under microscope at 0 h and at 48 h after being maintained in serum-free medium.

Trans-Well Assay
The 8-µm pore trans-well chamber (Corning, USA) was used for trans-well assay. Briefly, a total of 1 × 10⁶ U251 and U87 cells expressing with or without SH3KBP1 shRNA cells in serum-free medium were plated to the upper chamber. Simultaneously, DMEM culture medium with 20% FBS was added to the lower chamber. After culturing for 24 h, cells which invaded the lower chamber were fixed and stained with 1% crystal violet. Five random fields were pictured and migrated cells were counted.

EdU Assay
Proliferation ratio of the GBM cell lines was examined by using a Click-iTEdU Kit (Solarbio, CA1170) according to the manufacturer’s protocol. Briefly, 10 µM EdU was added into cells for 2 h before fixation and permeabilization. Cell nuclei were counterstained with Hoechst (Solarbio, C0021) at a concentration of 5 µg/ml for 30 min.

Quantitative Real Time PCR
Complementary DNA (cDNA) was obtained via reverse transcription of messenger RNA (mRNA), and cDNA were used as a template for quantitative real time PCR. Quantitative PCR kit was purchased from TIANGEN BioMart (Beijing, China). We detected mRNA expression level by quantitative PCR with ABI 7500 (Applied Biosystems). GAPDH was used as internal control. Sequences of PCR primers used in this study are shown as below. SH3KBP1 Forward primer: 5'-CATCGACGTAGGCTGGTG-3'. SH3KBP1 Reverse primer: 5'-CTTCTCTTTCATTAGCTCGGTG-3'. GAPDH Forward: 5'-GAGCGGAGATCCCCAAAT-3'. GAPDH Reverse: 5'-GGCTGTGTCATACTTCTCATGG-3'.

Western Blot
For Western blot assay, cells were harvested and lysed with RIPA buffer and protease inhibitors (Roche) and phosphatase inhibitors (Roche) were added into the RIPA buffer. After boiling for 5 min, the same quality of protein was loaded to SDS–PAGE gels and immunoblotting. GAPDH was used as loading control. After transferring to polyvinylidene fluoride membranes and blocking with 5% milk for 1 h at room temperature, the membranes were incubated with primary antibodies at 4°C for overnight, then incubated with HRP conjugated secondary antibodies. Antibodies used in this study were as shown below; SH3KBP1 (1:500) (12304), STAT3 (1:1,000) (9139), Phospho-STAT3 (1:500) (9212), Phospho-AKT (Ser473) (1:500) (4060), MAPK (1:1,000) (9211) and Phospho-MAPK (Tyr180) (1:500) (9211) all purchased from cell signaling technology.

Co-Immunoprecipitation
Cells were harvested and lysed with RIPA buffer containing protease inhibitors for 30 min at 4°C. Cell lysates were precleared by protein A/G beads (Santa Cruz Biotechnology) for 1 h incubation at 4°C, and precleared protein A/G beads were removed then primary antibody was added for overnight incubation at 4°C, and new protein A/G beads were added for 2 h incubation, then beads were collected by washing with ice cold PBS for four times. Finally, the bound protein was eluted by boiling for 10 min and subjected to SDS–PAGE and detected by immunoblotting. SH3KBP1 (1:500) (Cell signaling technology, 12304), EGFR (1:1,000) (Cell signaling technology, 4267).

In Vivo Tumor Growth Model
For intracranial tumor formation assay, Female NOD/SCID mice of 4–6 weeks were purchased from Shi Laike Company (Shanghai, China). 50,000 U87 cells were intracranially transplanted into the right cerebral cortex (coordinates: 2 mm anterior, 2 mm lateral, 3.5 mm depth from the dura). Mice were sacrificed when exhibiting neurological signs. For xenograft tumor formation assay, 4–6 weeks-old female BALB/c nude mice purchased from Shi Laike Company (Shanghai, China). Xenograft tumor model was created through subcutaneously injection with 1 × 10⁶ U87 cells expressed with control shRNA or SH3KBP1 shRNA to BALB/c nude mice. Tumor volume was recorded twice a week. Six weeks later, mice were sacrificed and tumors derived from indicated cells were collected, weighed and pictured. All animal studies were approved by the Animal Ethics Committee of Kunming Medical University.

Bioinformatic Analysis
To comprehensively explore the expression pattern and prognostic implications of SH3KBP1 in gliomas, transcriptome sequencing and corresponding clinical data of TCGA, CGGA and Rembrandt data sets were downloaded from http://gliovis.bioinfo.cnio.es/.

Statistical Analyses
Each assay was repeated independently for three times and experimental data were processed by Prism 7.0 software (GraphPad Software) and shown as mean ± S.E.M. The differences between groups were analyzed via Student’s t-test or one-way ANOVA and data were thought significantly different when P-value below 0.05. *, ** and *** indicate as p<0.05, p<0.005 and p<0.001 respectively.

RESULTS
Expression and Clinical Implications of SH3KBP1 in Glioma
To identify the potential biological functions of SH3KBP1 in glioma initiation and progression, we assessed the SH3KBP1 expression pattern in different grades of gliomas by using public datasets TCGA (22) and observed that SH3KBP1
expression positively correlates with tumor grades of glioma patients (Figure 1A). In addition, we performed Kaplan-Meier survival analysis in TCGA data set and the results showed a statistically significant worse prognosis for glioma patients with higher expression of SH3KBP1 compared with lower SH3KBP1 group patients (Figure 1B). It has been well recognized that patients with Isocitrate dehydrogenase1 (IDH1) mutant gliomas frequently have a favorable prognosis compared with wild-type (WT) IDH tumors’ patients (23). It is worth noting that, by comparing the expression of SH3KBP1 in IDH1 wild-type and mutant groups, we observed that SH3KBP1 was highly expressed in wild-type IDH1 tumors, implying that SH3KBP1 may play critical roles in glioma progression (Figure 1C). Consistently, we observed almost exactly the same patterns in CGGA (Figures 1D–F) and Rembrandt glioma datasets (Figures 1G, H). Glioma CpG island methylator phenotype (G-CIMP) is another widely accepted prognosis marker of gliomas and glioma patients with NON G-CIMP always predict poor prognosis, thus we compared the expression levels of SH3KBP1 in G-CIMP and NON G-CIMP group and found that SH3KBP1 was highly expressed in NON G-CIMP group (Figure 1I). Together, these data revealed that the expression level of SH3KBP1 is an indicator of the aggressiveness of malignant gliomas and SH3KBP1 could be used as a biomarker for glioma prognosis.

**SH3KBP1 Is Elevated in GSCs**

In order to examine the protein levels of SH3KBP1 in vivo, we performed immunohistochemistry (IHC) staining using 27
clinical glioma patients’ specimens, including nine WHO grade II, 10 WHO grade III, eight WHO grade IV. As shown in (Figure 2A and Table 1), SH3KBP1 staining was weak or negative in WHO grade II tumors. SH3KBP1 was expressed in majority of high-grade gliomas, particularly in GBM specimens. The quantification results indicated a strong positive association between the expression level of SH3KBP1 and glioma grade (Figure 2B).

Cancer stem cell (CSC) model suggests that a subpopulation cell residing in tumor is responsible for cancer initiation, therapeutic resistance and tumor relapse (6–8, 24). Thus, we wondered whether SH3KBP1 also plays essential roles in glioma stem cell (GSC). To test this hypothesis, we performed tumor spheres formation assay to enrich GSCs. Interestingly, we found that both SH3KBP1 mRNA and protein expression levels were dramatically increased in tumor spheres derived from U251, U87, and LN229 cells than their corresponding monolayer cells (Figures 2C–E), suggesting that SH3KBP1 plays critical roles in regulating GSCs self-renewal. Next, we validated this observation by performing immunofluorescence analysis in clinical GBM patients’ specimens and observed that SH3KBP1 are markedly co-expressed with SOX2, which is a known GSCs marker (Figures 2F, G). Consistent with this finding, we found that SH3KBP1 mRNA expression positively correlated with SOX2 mRNA expression in TCGA data set (Figure 2H) and CD133 and Oct4 mRNA (data not shown), which is also another widely recognized GSCs marker. Collectively, these data showed that SH3KBP1 is highly expressed in GBM and GSCs, which might be used as a new GSCs marker.

### SH3KBP1 Promotes GBM Cell Proliferation and Migration

To further study the biological function of SH3KBP1 in GBM development and progression, we used short hairpin RNA (shRNA)-expressing plasmids to generate stable SH3KBP1 knockdown clones in U251 and U87 cells. Silencing SH3KBP1 impeded U251 and U87 cell growth determined by EdU incorporation assay (Figures 3A, B). This finding was further confirmed by cell proliferation results. As shown in (Figure 3C), U251 and U87 SH3KBP1 silencing cells proliferation ratio was suppressed compared with its corresponding control cells. Consistently, colony formation ability was significantly

| Patients characteristics | No. of patients (%) |
|--------------------------|---------------------|
| Age (years)              |                     |
| ≤50                      | 12(44.5)            |
| >50                      | 15(55.4)            |
| Gender                   |                     |
| Male                     | 17(63.0)            |
| Female                   | 10(37.0)            |
| Clinical stages          |                     |
| Stage II                 | 9(33.3)             |
| Stage III                | 10(37)              |
| Stage IV                 | 8(30.0)             |

TABLE 1 | Clinicopathological characteristics of patients with glioma.
SH3KBP1 Directly Interacts With and Activates EGFR

Given that adaptor protein plays an essential role in regulating diverse signal transduction pathways, we speculated that biological function of SH3KBP1 may be dependent on binding with proteins having SRC homology domain. Thus, we examined whether SH3KBP1 directly interacts with EGFR, which is a well-known kinase with a SRC homology domain. We performed endogenous immunoprecipitation and western blot analysis and observed that SH3KBP1 binds to EGFR (Figure 4A), and EGFR also binds directly to SH3KBP1 (Figure 4B). Consistently, immunofluorescence also manifested the co-localization of SH3KBP1 with some endogenous EGFR on cell membrane of U87 cells (Figures 4C, D). In addition, we found that p-AKT, p-MAPK and p-STAT3, which are key downstream regulators of EGFR signaling pathways, were all simultaneously decreased after depletion of SH3KBP1 (Figures 4E, F), suggesting that SH3KBP1 may act as an adaptor protein that plays important roles in EGFR signaling transduction.
SH3KBP1 Enhances GBM Progression

In Vivo

To explore the potential functions of SH3KBP1 in GBM progression in vivo, we utilized an intracranially transplanted tumor xenograft model in NOD/SCID mice with U87 cells. We injected 50,000 U87 control or SH3KBP1 silencing cells into the brain of NOD/SCID nude mice and observed that those injected with SH3KBP1 shRNA-U87 cells displayed longer survival (Figure 5A). Xenograft tumor model were further performed to verify this observation and found that SH3KBP1 knockdown significantly inhibited tumor growth (Figures 5C, D) and tumor weight in xenograft mouse tumors (Figure 5B). Most importantly, immunohistochemistry assay was performed on tumors derived from mouse xenograft and found that SH3KBP1 silencing tumors exhibited a dramatic decrease in Ki67, a marker of proliferating cells, positive cells and p-STAT3 (Y705) than control tumors sections (Figures 5E–G). These data indicated that depletion of SH3KBP1 inhibits GBM tumorigenesis in vivo.

DISCUSSION

Glioblastoma is one of the most common and aggressive tumors in adults (2, 3). GBM is not a surgically curable disease as tumor cells invade the surrounding brain, which renders a completely impossible surgical resection. Furthermore, GBM tumors are among the most resistant tumors to radiation and cytotoxic chemotherapy (28, 29). Currently, survival time of GBM patients remains only at 15 months despite aggressive surgical resection and conventional therapy (30). Thus, a deeper understanding of molecular mechanism involved in GBM initiation and development is essential for development of more effective therapies for this lethal disease.

Numerous studies have reported that EGFR activation promotes multiple tumor progression (14, 31). Activation of EGFR by binding with ligand or mutation is essential for tumor cell proliferation, migration and cancer stem cell self-renewal. GBM has been characterized by amplification or activation of EGFR (32, 33). EGFR drives tumorigenesis by multiple downstream signaling pathways thereby stimulating cancer cell proliferation, survival and chemoresistance (34). In this study, we report a novel function of SH3KBP1, acting as a new downstream effector of EGFR signaling to mediate EGFR-driven tumorigenesis. We demonstrate that both mRNA and protein levels of SH3KBP1 are highly expressed in GBM (WHO IV) patients than gliomas (WHO II and III) patients and its high expression predicts poor survival of glioma patients. Furthermore, SH3KBP1 was also upregulated in tumor spheres than monolayer cells and plays critical roles in GSCs self-renewal and stemness maintenance. The importance of this
high expression is highlighted by the co-expression of SH3KBP1 and SOX2 in glioma clinical samples. Hodonsky et al. reported that SOX10 binds to SH3KBP1 promoter and regulates SH3KBP1 expression in a transcriptional level (35). Additionally, SOX10 has been identified to play essential roles in cancer stem cell self-renewal (36, 37). Thus, the high expression of SH3KBP1 in GBM may be attributed to SOX10 high expression in GBM and the mechanisms mediating SH3KBP1 overexpression in glioma and GSCs needs further characterized. Recently, Yao et al. found that EGFR blockade prevents glioma escape from BRAFV600E targeted therapy (38). EGFR inhibitor significantly enhances cisplatin sensitivity of human glioma cells (39). GATA2, hematopoietic factor and gain of function assay revealed that GATA2 significantly enhanced proliferation, migration and invasion of glioma cells by activating EGFR signaling. Glioma patients accepted EGFR-targeted therapy have favorable clinical outcomes (40). However, EGFR mutations in GBM are fully virtually clustered in the extracellular domain and cause the receptor to adopt an inactive conformation. Pharmacological factors and EGFR inhibitors which did not achieve favorable clinical outcomes were caused by the inactive conformation. Thus, there is an urgent need to identify new agents targeting EGFR downstream genes or adaptor proteins as clinically applicable targets to develop to clinical therapy. Sang et al. identified TRIM59 as a new regulator of oncogenic EGFR signaling and silencing TRIM59 inhibits gliomagenesis by inhibiting dephosphorylation of STAT3 (41). However, detailed molecular mechanism of EGFR signaling activation by SH3KBP1 should be further investigated. Taken together, our study provides clinical and mechanistic evidence demonstrating that SH3KBP1 high expression is essential for EGFR driven tumorigenesis in glioma. In this study, we provide evidence that silencing SH3KBP1 significantly inhibits GBM cells proliferation, migration and GSCs spheres formation by functioning as adaptor protein transduces the EGFR signaling. Additionally, targeting SH3KBP1 markedly inhibits EGFR downstream signaling, including p-AKT, p-ERK and p-MAPK expression level (Figure 6). Consistently, Feng et al. found that SH3KBP1 prevents epidermal growth factor receptor degradation and activates EGFR signaling (19). EGFR is a well-accepted kinase that plays key roles in glioma cell proliferation and migration and SH3KBP1 activates EGFR signaling. Thus, we concluded that SH3KBP1 promotes glioma progression dependent on SH3KBP1-EGFR axis (Figure 6). Inhibitors or drugs that specifically decrease the expression of SH3KBP1 in glioma cells may be developed to increase the lifespan of glioma patients. In the near future, we will focus on screening those inhibitors specifically to determine their inhibitory effect on EGFR/SH3KBP1 signaling. This study therefore presents evidence.

**FIGURE 5** | Depletion of SH3KBP1 inhibits mouse xenograft tumor growth *in vivo*. (A) Kaplan-Meier survival analysis of mice intracranially implanted with U87 cells with or without SH3KBP1 knockdown. n = 5, log-rank (Mantel-Cox) test. (B) Tumor weight was measured in mice after the mouse was sacrificed. (C) SH3KBP1 knockdown significantly inhibited mouse xenograft tumor growth. (D) Representative tumors derived from indicated cells were imaged. n = 5. (E) Immunohistochemistry staining analysis of Ki67, and p-STAT3 in U87 cells derived mouse xenograft tumors. Five tumors from each group were analyzed. (F, G) Quantitative data for (E). ** and *** indicate as p < 0.05, p < 0.005 and p < 0.001 respectively.
showing that SH3KBP1 not only can be used as a diagnostic marker but also as a target for therapy in future.

In conclusion, our findings reveal a previously unknown signal relay by which SH3KBP1 mediates EGFR activation, thereby enhancing the oncogenic activity of the EGFR signaling pathway in human gliomas. The newly established roles of SH3KBP1 in EGFR-driven tumorigenesis provide a rationale for SH3KBP1 as a novel prognostic marker for patients with glioma and a potential target for further therapeutic investigation.

REFERENCES

1. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The Somatic Genomic Landscape of Glioblastoma (Vol 155, pg 462, 2013). Cell (2014) 157(3):753–3.
2. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol (2014) 9:1–25. doi: 10.1146/annurev-pathol-011110-130324
3. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 45(10):1141–9. doi: 10.1038/ng.2734
4. Stupp R, Mason WP, van den Beuf MJ. Radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma (vol 352, pg 19, 2005). Ann Oncol (2005) 16(6):949–9.
5. Ali BDS, Wu QL, Mclendon RE, Hao YL, Shi Q, Hjelmeland AB, et al. The DNA damage response by preferential activation of the DNA repair pathways in glioma stem cells. Nature (2006) 444(7120):756–60. doi: 10.1038/nature05236
6. Xu H, Wang Q, Wang YA, Hua S, Sauve CG, Ong D, et al. Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell (2016) 167(5):1281–95.e18. doi: 10.1016/j.cell.2016.10.039
7. Hu B, Wang Q, Wang YA, Hua S, Sauve CG, Ong D, et al. Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell (2016) 167(5):1281–95.e18. doi: 10.1016/j.cell.2016.10.039
8. Chen J, Li YJ, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature (2012) 488(7412):522–6. doi: 10.1038/nature11287
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646–74. doi: 10.1016/j.cell.2011.02.013
10. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 25(3):282–303. doi: 10.1016/j.ccr.2014.02.025
11. Singh B, Coffey RJ. Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells. Annu Rev Physiol (2014) 76:275–300. doi: 10.1146/annurev-physiol-021113-170406
12. Moscatello DK, Holgadomadruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, et al. Frequent Expression of a Mutant Epidermal Growth-Factor Receptor in Multiple Human Tumors. Cancer Res (2015) 75(23):5536–9.
13. Suzuki H, Hiroshima T, Okamoto N, Yamadori T, Tamiya M, Kawase I. The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations. Chin J Cancer (2013) 32(3):136–40. doi: 10.5732/cjc.012.10160
14. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer (2001) 37(Suppl 4):59–15. doi: 10.1016/S0959-8049(01)00231-3
15. Lu ZM, Jiang GQ, Blume-Jensen P, Hunter T. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol (2001) 21(12):4016–31. doi: 10.1128/MCB.21.12.4016-4031.2001

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of First Affiliated Hospital of Kunming Medical University. The patients provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

XW designed the study, analyzed data and wrote the manuscript. HS performed almost all experiments. YW performed database analysis. CS, TY, and JL collected GBM clinical samples and performed IHC assay. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported in part by Grants from (1) Health Commission of Yunnan Province Training plan for Medical Reserve Talents (H-2017029. (2) Yunnan Health Science and Technology Project (internal organization) (2017NS058). (3) Research Innovation team of Yunnan province (2019HC022). (4) Yunnan clinical medical center of nervous system diseases (ZX2019-03-05).
16. Zheng YH, Li XJ, Qian X, Wang YG, Lee JH, Xia Y, et al. Secreted and O-GlcNAcylated MIF binds to the human EGF receptor and inhibits its activation. *J Cell Biol* (2011) 195(3):591–600. doi: 10.1083/jcb.201109024

17. Liu Z, Liu Z, Tan X, Li C. SH3GL3 functions as a potent tumor suppressor in lung cancer in a SH3 domain dependent manner. *Biochem Biophys Res Commun* (2020) 534:787–94. doi: 10.1016/j.bbrc.2020.10.107

18. Kong MS, Hashimoto-Tane A, Kawashima Y, Sakuma M, Yokosuka T, Kometani K, et al. Inhibition of T cell activation and function by the adaptor protein CIN85. *Sci Signal* (2012) 6(245):ra4437. doi: 10.1126/scisignal.24373

19. Feng L, Wang JT, Jin H, Qian K, Geng JG. SH3KBP1-binding protein 1 prevents epithelial growth factor receptor degradation by the interruption of c-Cbl-SH3 domain binding motif in the lysyl oxidase propeptide. *PLoS One* (2013) 8(10):e77288. doi: 10.1371/journal.pone.0077288

20. Kozlova N, Mennerich D, Samoylenko A, Dimova EY, Koivunen P, Biterova E, et al. The Pro-Oncogenic Adaptor CIN85 Acts as an Inhibitory Binding Partner of Hypoxia-Inducible Factor Prolyl Hydroxylase 2. *Cancer Res* (2019) 79(16):4042–56. doi: 10.1158/0008-5472.CAN-18-3852

21. Sato S, Zhao Y, Imai M, Simister PC, Feller SM, Trackman PC, et al. Inhibition of CIN85-mediated invasion by a novel SH3 domain binding motif in the lysyl oxidase propeptide. *PLoS One* (2013) 8(10):e77288. doi: 10.1371/journal.pone.0077288

22. Brat DJ, Verhaak RGW, Al-Dape KD, Yung WKA, Salama SR, Chin L, et al. Cancer Genome Architecture of Diffuse Lower-Grade Gliomas. *N Engl J Med* (2015) 372(26):2481–98. doi: 10.1056/NEJMoa1402121

23. Hartmann C, Meyer J, Balss J, Weiler M, Blaes J, Jestaedt L, Liu HK. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. *Cell Stem Cell* (2014) 15(1):185–98. doi: 10.1016/j.stem.2014.04.007

24. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of brain metastases from the perspective of a neurosurgeon. *Neuropathol Appl Neurobiol* (2012) 38(3):271–91. doi: 10.1111/j.1365-2990.2011.01238.x

25. Zhu Z, Khan MA, Weiler M, Blaes J, Jestaedt L, Liu HK. Targeting self-renewal in high-grade gliomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. *J Clin Oncol* (2005) 23(10):2411–22. doi: 10.1200/JCO.2005.03.089

26. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. *J Clin Oncol* (2003) 21(8):1624–36. doi: 10.1200/JCO.2003.05.063

27. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. *Clin Cancer Res* (2009) 15(14):5489–99. doi: 10.1158/1078-0432.CCR-09-0575

28. Dunn GP, Rinne KD, Wykosky J, Genovesi G, Quayle SN, Hahn WC. Emerging insights into the molecular and cellular basis of glioblastoma. *Genes Dev* (2012) 26(8):756–84. doi: 10.1101/gad.187922.112

29. Masui K, Cloughesy TF, Mischel PS. Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. *Neuropathol Appl Neurobiol* (2012) 38(3):271–91. doi: 10.1111/j.1365-2990.2011.01238.x

30. Oike T, Suzuki Y, Sugawara K, Shirai K, Noda S, Tamaki T, et al. Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono- Institutional Results. *PLoS One* (2013) 8(11):e78943. doi: 10.1371/journal.pone.0078943

31. Sharma V, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer* (2007) 7(5):169–81. doi: 10.1038/nrc2088

32. Lee JC, Vivanco I, Beroukhim R, Huang JHY, Feng WL, DeBiasi RM. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. *PLoS Med* (2006) 3(12):2264–73.

33. An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRVIII in glioblastoma: signaling pathways and targeted therapies. *Oncogene* (2018) 37(12):1561–75. doi: 10.1038/s41388-017-0045-7

34. Dunn GP, Rinne KD, Wykosky J, Genovesi G, Quayle SN, Hahn WC. Emerging insights into the molecular and cellular basis of glioblastoma. *Genes Dev* (2012) 38(3):271–91. doi: 10.1038/nrc2088

35. Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, et al. EGFR phosphorylates tumor-derived EGFRVIII driving STAT3/5 and progression in glioblastoma. *Cancer Cell* (2013) 24(4):438–49. doi: 10.1016/j.ccr.2013.09.004

36. Hodonsky CJ, Kleinbrink EL, Charney KN, Prasad M, Bessling SL, Jones EA, et al. SOX10 regulates expression of the SH3-domain kinase binding protein 1 (Sh3kbp1) locus in Schwann cells via an alternative promoter. *Mol Cell Neurosci* (2012) 49(2):85–96. doi: 10.1016/j.mcn.2011.10.004

37. Dravis C, Spike BT, Harrelle JC, Johns C, Trejo CL, Southard-Smith EM, et al. SOX10 regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells. *Cell Rep* (2015) 12(12):2035–48. doi: 10.1016/j.celrep.2015.08.040

38. Feng W, Liu S, Zhu R, Li B, Zhu Z, Yang J, et al. SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells. *Biochem Biophys Res Commun* (2017) 485(2):522–8. doi: 10.1016/j.bbrc.2017.02.014

39. Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T, et al. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. *Oncotarget* (2015) 6(26):21993–2005. doi: 10.18632/oncotarget.4014

40. Zhang Y, Xing X, Zhan H, Li Q, Fan Y, Zhan L, et al. EGFR inhibitor enhances cisplatin sensitivity of human glioma cells. *J Huazhong Univ Sci Technolog Med Sci* (2012) 31(6):773–80. doi: 10.1007/s11596-011-0675-x

41. Lo HW. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. *Curr Mol Pharmacol* (2015) 8(1):37–52. doi: 10.2174/1874467211003010037

42. Hung MC, Wang S, Lin Y, Chen C, Lin CY, Lu H, et al. TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3. *Cancer Res* (2018) 78(7):1792–804. doi: 10.1158/0008-5472.CAN-17-2774

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Song, Wang, Shi, Lu, Yuan and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.